| Document |
Document Title |
|
WO/2022/051565A1 |
The invention provides substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disor...
|
|
WO/2022/047014A1 |
The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic ...
|
|
WO/2022/043322A1 |
The present invention relates to compounds of formula (la) and the use thereof as inhibitors of P. aeruginosa virulence factor LasB. Formula (la). These compounds are useful in the treatment of bacterial infections, especially caused by ...
|
|
WO/2022/040747A1 |
The present invention relates to compounds that have zinc and/or iron ionophore activity and their use in treating diseases that are modulated by reducing zinc and/or iron. In particular embodiments, the compounds are compounds of formul...
|
|
WO/2022/045618A1 |
Provided is a tertiary amine derivative, which effectively absorbs high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contributes to a substantia...
|
|
WO/2022/037927A1 |
New isobutyramides.
|
|
WO/2022/038356A1 |
The present invention relates to compounds of Formula (I) that function as LMO2 activity: Formula (I) wherein R1, X1, X2, X3, Q, R2, R3 and R4 are each as defined herein. The present invention also relates to processes for the preparatio...
|
|
WO/2022/040324A1 |
The present disclosure is generally directed to modulators of hydroxysteroid dehydrogenase enzymes useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I), Formula (II), or Formula (III).
|
|
WO/2022/027058A1 |
The present invention relates to methods of treating MYD88-mutant B-cell lymphomas using IRAK4 degraders.
|
|
WO/2022/023439A1 |
This invention relates to radiolabelled compounds as described herein, precursor compounds and reference compounds, as well as pharmaceutical compositions comprising the radiolabelled compounds, which are for use in a diagnostic method p...
|
|
WO/2022/017515A1 |
Provided in the present application are a diarylamine compound, a preparation method therefor and an application thereof. The compound has a structure represented by formula 1; R1 is selected from an alkyl group of C1-12, an alkoxy group...
|
|
WO/2022/020243A1 |
The present invention refers to: crystalline tizoxanide amine salts, such as e.g. the ethanolamine salt, the morpholine salt, the propanolamine salt, the piperazine salt and the N-methylpiperazine salt, crystalline amine salts of 2-hydro...
|
|
WO/2022/020716A1 |
The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
|
|
WO/2022/020272A1 |
Disclosed herein are particles and methods of using said particles in assays for detection of biomolecules in a sample. Various methods of the present disclosure utilize particles for biomolecule adsorption. In some aspects, the present ...
|
|
WO/2022/013919A1 |
The purification method according to the present invention is for selectively obtaining a specific crystal form of a compound having a plurality of crystal forms. Specifically, in an infrared absorption spectrum of a plurality of crystal...
|
|
WO/2022/014395A1 |
This refining method involves crystallizing a compound that has at least one crystalline form, wherein: a specific infrared wavelength, at which a specific crystalline form precipitates from a solution obtained by dissolving the compound...
|
|
WO/2022/014397A1 |
This refining method is for crystallizing a compound having at least one crystal form. A specific infrared wavelength and a specific concentration at which a specific crystal form precipitates from a solution in which the compound is dis...
|
|
WO/2022/014396A1 |
A purification method according to the present invention is a purification method that brings about the crystallization of a compound that has at least one crystalline form. A prescribed infrared wavelength and prescribed temperature at ...
|
|
WO/2022/008006A1 |
The invention relates to compounds of the general formula (I) wherein X1 is a CD2 group or a CT2 group; X2 is oxygen or a group (CZ1Z2)n, with Z1 and Z2 independently of each other being hydrogen, deuterium or tritium and n being an inte...
|
|
WO/2022/007168A1 |
The present application relates to a benzo five-membered nitrogen heterocyclic compound and an application thereof. The benzo five-membered nitrogen heterocyclic compound has the structure represented by formula I. The compound can be us...
|
|
WO/2022/004744A1 |
The present invention addresses the problem of providing a novel compound that can be used as a luminescent substrate in a firefly bioluminescence system and that can emit light with high brightness. In order to solve the problem, this h...
|
|
WO/2021/263079A1 |
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds for inhibiting three prime repair exonuclease 1 ("TREX1").
|
|
WO/2021/261851A1 |
The present invention provides an organic electric element and an electronic device comprising the organic electric element, the organic electric element comprising an anode, a cathode, and an organic layer and a capping layer formed bet...
|
|
WO/2021/256899A1 |
The present invention relates to a novel fused heterocyclic carbonohydrazonoyl dicyanide compound and a use thereof.
|
|
WO/2021/255011A1 |
The invention relates to an improved process for the manufacture of alkylamidothiazoles. This novel economical process provides products in high purity and yields.
|
|
WO/2021/249234A1 |
A compound represented by general formula (I) or stereisomers thereof and pharmaceutically acceptable salts, solvates or prodrugs thereof, a preparation method therefor and a pharmaceutical composition containing the compound. An applica...
|
|
WO/2021/252309A1 |
The present disclosure relates to a) crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thia
zol-5-ylsulfanyl}-acetic acid ("Compound I "); b) pharmaceutical compositions, comprising one or more crystalline form...
|
|
WO/2021/252555A1 |
The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound heali...
|
|
WO/2021/251661A1 |
The present invention provides a novel compound and an organic light emitting device comprising same.
|
|
WO/2021/252311A1 |
Sodium, piperazine, and hydrochloride salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thia
zol-5-ylsulfanyl}-acetic acid ("Compound 1") are provided herein.
|
|
WO/2021/249337A1 |
Disclosed in the present invention is a series of dimethylsulfoximine derivatives, and specifically disclosed are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.
|
|
WO/2021/247634A1 |
Provided herein are compounds of Formula (I''), Formula (I'), Formula (I), Formula (II'), and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labele...
|
|
WO/2021/247921A1 |
The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurolo...
|
|
WO/2021/247732A1 |
The present invention relates to compounds of formula I (I) as well as to the compounds of formula I for use as transmembrane serine protease 2 (TMPRSS2) inhibitors in the treatment of viral infections, such as e.g. corona virus infectio...
|
|
WO/2021/246974A1 |
The present invention relates to 2-(3-(2-Methyl-6-(p-tolyl) pyridine-3-yl) ureido) benzenesulfonamide (formula I) compound and related pyridine based sulfonamide derivatives. The compound of the invention is a carbonic anhydrase targeted...
|
|
WO/2021/234497A1 |
The present disclosure relates to a process for the purification of a crude 2-mercaptobenzothiazole. The process comprises purifying the crude 2-mercaptobenzothiazole by using a suitable fluid medium to obtain pure 2-mercaptobenzothiazol...
|
|
WO/2021/230512A1 |
Provided is a benzazole derivative that effectively absorbs a high-energy external light source in a UV region so as to minimize damage to organic materials inside an organic electroluminescent device, thereby contributing to a substanti...
|
|
WO/2021/230511A1 |
Provided is a benzazole derivative which contributes to improving substantial optical efficiency and viewing angle of an organic electroluminescent device. An organic electroluminescent device according to the present invention comprises...
|
|
WO/2021/224934A1 |
Disclosed is a process (100) for conversion of N-tertiary butyl acrylamide to tert-butylamine and salts of propionic acid. The process comprises of first selectively reducing the vinylic double bond in N-tertiary butyl acrylamide by cata...
|
|
WO/2021/222366A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2021/218110A1 |
A benzothiazolyl biaryl compound represented by general formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, a diastereoisomer, a tautomer, a torsional isomer, a solvate, a polymorph, or a prodrug thereof, a prepar...
|
|
WO/2021/215480A1 |
The present invention provides a control method effective against plant diseases. In the present invention, compounds represented by Formula (I) (wherein Z represents a C1-C6 chain hydrocarbon group or the like, Q represents a group repr...
|
|
WO/2021/216402A1 |
The invention provides pharmaceutical compositions and dosage forms of fluorocarbon emulsions that are useful for treating viral infections and acute respiratory distress syndrome and related diseases and conditions, as well as methods o...
|
|
WO/2021/212734A1 |
Disclosed in the present invention are an application of a mixed N-heterocyclic carbene-based nickel (II) complex in a reaction for synthesizing a 2-linear alkylbenzothiazole compound, and a method for synthesizing a 2-linear alkylbenzot...
|
|
WO/2021/215624A1 |
The present invention provides a novel 2-arylthiazole derivative having a specific carboxamide moiety, for example, a substituted aminoalkyl-carboxamide moiety, a N-bearing heterocyclic alkyl-carboxamide moiety, or a N-bearing heterocycl...
|
|
WO/2021/214019A1 |
The present invention covers aminothiazole compounds of general formula (I), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutica...
|
|
WO/2021/214020A1 |
The present invention covers aminothiazole compounds of general formula (I) : in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutic...
|
|
WO/2021/217036A1 |
A molecule comprising a G-protein coupled estrogen receptor (GPER) ligand coupled to a linker coupled to an E3 ubiquitin ligase ligand and methods of using the molecule are provided. In one embodiment, the GPER ligand is estradiol and th...
|
|
WO/2021/212054A1 |
Provided herein are thiazolidinedione analogues that are useful for treating metabolic disorders and/or coronavirus infections. In some embodiments, the metabolic disorder includes insulin resistance, diabetes, or prediabetes. In some em...
|
|
WO/2021/211706A1 |
A chelate and associated security feature including a lanthanide metal and a ligand of formula (1), formula (2), or formula (3), where each of R1-R7 in formula (1) is independently selected from the group consisting of H, OH, NH2, Cl, F,...
|
